Statement: the secondary trial and the primary trial are both testing Biodesign interventions.
Primary_evidence: INTERVENTION 1:    LA-EP2006   During each chemotherapy cycle eligible patients receive LA-EP2006 s.c. post chemotherapy application.   LA-EP2006: Eligible patients are scheduled to receive six cycles of chemotherapy every three weeks. During each chemotherapy cycle pegfilgrastim is injected s.c. post chemotherapy application. INTERVENTION 2:    Neulasta®   During each chemotherapy cycle eligible patients receive Neulasta® s.c. post chemotherapy application.   Neulasta®: Eligible patients are scheduled to receive six cycles of chemotherapy every three weeks. During each chemotherapy cycle pegfilgrastim is injected s.c. post chemotherapy application.
Secondary_evidence: INTERVENTION 1:    Nipple Reconstruction Cylinder   Nipple reconstruction: Biodesign® Nipple Reconstruction Cylinder